# SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 Q2 P&L / Income Statement

- Company: SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001356576-26-000037
- Page: https://plicit.ai/financials/supn/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/supn-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service (9 categories)

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (9 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 219,058,000 US dollars
- **Cost of revenues**: 33,669,000 US dollars
- **Gross profit (calculated)**: 185,389,000 US dollars
- **Operating expenses (calculated)**: 243,352,000 US dollars
- **Operating earnings (loss)**: negative 57,963,000 US dollars
- **Total other income, net**: 315,000 US dollars
- **Earnings (loss) before income taxes**: negative 57,648,000 US dollars
- **Income tax expense (benefit)**: 723,000 US dollars
- **Net earnings (loss)**: negative 58,371,000 US dollars
- **Collaboration revenue (ZURZUVAE)**: 35,350,000 US dollars
- **Royalty, licensing, and other revenues**: 17,995,000 US dollars
- **Qelbree**: 89,239,000 US dollars
- **GOCOVRI**: 37,530,000 US dollars
- **ONAPGO**: 13,546,000 US dollars
- **Trokendi XR**: 8,411,000 US dollars
- **Oxtellar XR**: 8,782,000 US dollars
- **APOKYN**: 6,323,000 US dollars
- **Other**: 1,882,000 US dollars
- **Research and development**: 29,463,000 US dollars
- **Selling, general and administrative**: 133,637,000 US dollars
- **Amortization of intangible assets**: 25,333,000 US dollars
- **Intangible asset impairment charges**: 54,919,000 US dollars
- **Contingent consideration loss**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (3 categories)

- Page: https://plicit.ai/financials/supn/fy2026-q2-income-statement/revenue-by-product-and-service-3-categories
- Chart image: https://plicit.ai/charts/supn-fy2026-q2-revenue-by-product-and-service-3-categories-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (3 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 219,058,000 US dollars
- **Cost of revenues**: 33,669,000 US dollars
- **Gross profit (calculated)**: 185,389,000 US dollars
- **Operating expenses (calculated)**: 243,352,000 US dollars
- **Operating earnings (loss)**: negative 57,963,000 US dollars
- **Total other income, net**: 315,000 US dollars
- **Earnings (loss) before income taxes**: negative 57,648,000 US dollars
- **Income tax expense (benefit)**: 723,000 US dollars
- **Net earnings (loss)**: negative 58,371,000 US dollars
- **Net product sales**: 165,713,000 US dollars
- **Collaboration revenue (ZURZUVAE)**: 35,350,000 US dollars
- **Royalty, licensing, and other revenues**: 17,995,000 US dollars
- **Research and development**: 29,463,000 US dollars
- **Selling, general and administrative**: 133,637,000 US dollars
- **Amortization of intangible assets**: 25,333,000 US dollars
- **Intangible asset impairment charges**: 54,919,000 US dollars
- **Contingent consideration loss**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.